Figure 3.The miR-497 inhibitor significantly reduced the cytotoxicity of gemcitabine. The CSCs or non-CSCs of AsPC-1 and BxPC-3 cells transfected with the NC or miR-497 inhibitor were treated with gemcitabine for 0, 12, or 24 h, after which cell viability was determined by CCK-8 assay NC, negative control; CSCs, cancer stem cells; *p < 0.05, **p < 0.01 compared with NC + gemcitabine.
